Originally published byEU-Startups
STORM Therapeutics (STORM), a Cambridge-based BioTech company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced that it has secured €47.5 million ($56 million) in Series C financing. The financing was secured from existing investors, M Ventures, Pfizer Ventures, Taiho Ventures LLC, IP Group plc, the UTokyo Innovation Platform Co., Ltd. […]
The post STORM Therapeutics raises €47.5 million Series C to harness the power of RNA modification to treat cancer appeared first on EU-Startups.
🌐
More news from European UnionEuropean Union
EUROPE
Related News
Intel eases reliance on TSMC with 'Merica-made Core Series 3 processors
April 17, 2026
Cloudflare can remember it for you wholesale
April 18, 2026
Opsec oopsie: Dutch navy frigate location outed by mailing it a Bluetooth tracker
April 17, 2026
Britain puts €573 million on the table as Sovereign AI names its first startup cohort
April 17, 2026
Stockholm’s BioLamina secures €20 million EIB loan to scale cell therapies for chronic diseases
April 17, 2026